BioXcel Therapeutics (FRA:BX2) ROCE % : -138.38% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioXcel Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -138.38%.

BioXcel Therapeutics ROCE % Historical Data

The historical data trend for BioXcel Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics ROCE % Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-99.98

-68.83

-51.38

-82.53

-147.66

BioXcel Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-101.27	-121.24	-155.53	-229.26	-138.38

BioXcel Therapeutics ROCE % Calculation

BioXcel Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-151.983	/	( ( (194.325 - 31.056)	+	(67.585 - 25.004) )	/ 2 )
	=	-151.983	/	( (163.269	+	42.581)	/ 2 )
	=	-151.983	/	102.925
	=	-147.66 %

BioXcel Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-69.036	/	( ( (94.121 - 36.925)	+	(67.585 - 25.004) )	/ 2 )
	=	-69.036	/	( ( 57.196	+	42.581 )	/ 2 )
	=	-69.036	/	49.8885
	=	-138.38 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

BioXcel Therapeutics (FRA:BX2) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioXcel Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BTAI:USA BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines